home > drugs a-z list > clarinex (desloratadine) drug center > clarinex (desloratadine) drug - side effects and drug interactions

Adults and Adolescents

Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2,834 patients ages 12 years or older received CLARINEX (desloratadine) Tablets at doses of 2.5 mg to 20 mg daily, of whom 1,655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between CLARINEX (desloratadine) and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the CLARINEX (desloratadine) group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of CLARINEX (desloratadine) Tablets (5.0 mg once-daily), and that were more common with CLARINEX (desloratadine) Tablets than placebo, are listed in Table 5.

Table 5: Incidence of Adverse Events Reported by 2% or More of Adult and Adolescent Allergic Rhinitis Patients in Placebo-Controlled, Multiple-Dose Clinical Trials with the Tablet Formulation of CLARINEX (desloratadine)

The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in CLARINEX (desloratadine) and placebo-treated patients.

There were no differences in adverse events for subgroups of patients as defined by gender, age, or race.

Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urticaria, 211 patients ages 12 years or older received CLARINEX (desloratadine) Tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received CLARINEX (desloratadine) Tablets and that were more common with CLARINEX (desloratadine) than placebo were (rates for CLARINEX (desloratadine) and placebo, respectively): headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).

Pediatrics

Two hundred and forty-six pediatric subjects 6 months to 11 years of age received CLARINEX (desloratadine) Syrup for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day. In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects. In subjects 2 to 5 years of age, adverse events reported for CLARINEX (desloratadine) and placebo in at least 2 percent of subjects receiving CLARINEX (desloratadine) Syrup and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%), and varicella (3.6%, 0%). In subjects 12 months to 23 months of age, adverse events reported for the CLARINEX (desloratadine) product and placebo in at least 2 percent of subjects receiving CLARINEX (desloratadine) Syrup and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%). In subjects 6 months to 11 months of age, adverse events reported for CLARINEX (desloratadine) and placebo in at least 2 percent of subjects receiving CLARINEX (desloratadine) Syrup and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%). There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pedi-atric subjects receiving CLARINEX (desloratadine) Syrup in the clinical trials discontinued treatment because of an adverse event.

Observed During Clinical Practice

The following spontaneous adverse events have been reported during the marketing of desloratadine: tachycardia, palpitations, rare cases of hypersensitivity reactions (such as rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis), psychomotor hyperactivity, seizures, and elevated liver enzymes including bilirubin, and very rarely, hepatitis.

Drug Abuse And Dependence

There is no information to indicate that abuse or dependency occurs with CLARINEX (desloratadine) Tablets.

No information provided.

Last reviewed on RxList: 7/10/2009
This monograph has been modified to include the generic and brand name in many instances.